nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—RYR3—diaphragm—liver cancer	0.373	0.956	CbGeAlD
Dantrolene—RYR3—Stimuli-sensing channels—SLC9C1—liver cancer	0.0324	0.0929	CbGpPWpGaD
Dantrolene—RYR1—Stimuli-sensing channels—SLC9C1—liver cancer	0.0239	0.0685	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—SLC9C1—liver cancer	0.0212	0.0606	CbGpPWpGaD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—JUN—liver cancer	0.0158	0.0452	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—SLC9C1—liver cancer	0.0156	0.0447	CbGpPWpGaD
Dantrolene—RYR1—liver—liver cancer	0.0145	0.0371	CbGeAlD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GJB1—liver cancer	0.0122	0.035	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—ADAM17—liver cancer	0.0105	0.0302	CbGpPWpGaD
Dantrolene—RYR3—Ion channel transport—ATP7B—liver cancer	0.0099	0.0284	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GJB1—liver cancer	0.009	0.0258	CbGpPWpGaD
Dantrolene—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.00877	0.0251	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—CYCS—liver cancer	0.00848	0.0243	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00736	0.0211	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00736	0.0211	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—ATP7B—liver cancer	0.0073	0.0209	CbGpPWpGaD
Dantrolene—Pleural effusion—Sorafenib—liver cancer	0.0073	0.0279	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—ATF3—liver cancer	0.00685	0.0196	CbGpPWpGaD
Dantrolene—Dysphonia—Sorafenib—liver cancer	0.00679	0.026	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00543	0.0156	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00543	0.0156	CbGpPWpGaD
Dantrolene—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00527	0.0151	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—ATF3—liver cancer	0.00505	0.0145	CbGpPWpGaD
Dantrolene—Pericarditis—Epirubicin—liver cancer	0.00477	0.0183	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—PRKCE—liver cancer	0.00462	0.0132	CbGpPWpGaD
Dantrolene—Hepatic failure—Sorafenib—liver cancer	0.00451	0.0173	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—PRKCE—liver cancer	0.00448	0.0128	CbGpPWpGaD
Dantrolene—Pericarditis—Doxorubicin—liver cancer	0.00442	0.0169	CcSEcCtD
Dantrolene—Cardiac failure—Sorafenib—liver cancer	0.00416	0.0159	CcSEcCtD
Dantrolene—Pain in extremity—Sorafenib—liver cancer	0.00406	0.0155	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00377	0.0108	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.0036	0.0103	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—CASP3—liver cancer	0.00359	0.0103	CbGpPWpGaD
Dantrolene—Dysphagia—Sorafenib—liver cancer	0.00351	0.0134	CcSEcCtD
Dantrolene—RYR3—Stimuli-sensing channels—RAF1—liver cancer	0.00345	0.0099	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00345	0.00988	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00345	0.00988	CbGpPWpGaD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—PRKCE—liver cancer	0.00341	0.00977	CbGpPWpGaD
Dantrolene—Eruption—Epirubicin—liver cancer	0.00336	0.0129	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—PRKCE—liver cancer	0.0033	0.00946	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00326	0.00934	CbGpPWpGaD
Dantrolene—Eruption—Doxorubicin—liver cancer	0.00311	0.0119	CcSEcCtD
Dantrolene—Renal failure—Sorafenib—liver cancer	0.00307	0.0118	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.0029	0.00833	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00286	0.00819	CbGpPWpGaD
Dantrolene—Haemoglobin—Sorafenib—liver cancer	0.00282	0.0108	CcSEcCtD
Dantrolene—Haemorrhage—Sorafenib—liver cancer	0.00281	0.0107	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00278	0.00796	CbGpPWpGaD
Dantrolene—Pleural effusion—Epirubicin—liver cancer	0.0027	0.0103	CcSEcCtD
Dantrolene—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00266	0.00762	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00265	0.0076	CbGpPWpGaD
Dantrolene—Necrosis—Epirubicin—liver cancer	0.00263	0.0101	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TNF—liver cancer	0.00261	0.00749	CbGpPWpGaD
Dantrolene—Flushing—Sorafenib—liver cancer	0.0026	0.00998	CcSEcCtD
Dantrolene—RYR1—Stimuli-sensing channels—RAF1—liver cancer	0.00255	0.0073	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00254	0.00728	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00254	0.00728	CbGpPWpGaD
Dantrolene—CYP3A4—liver—liver cancer	0.00252	0.00645	CbGeAlD
Dantrolene—Dysphonia—Epirubicin—liver cancer	0.00251	0.00961	CcSEcCtD
Dantrolene—Pleural effusion—Doxorubicin—liver cancer	0.00249	0.00956	CcSEcCtD
Dantrolene—Erythema—Sorafenib—liver cancer	0.00244	0.00936	CcSEcCtD
Dantrolene—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00244	0.00699	CbGpPWpGaD
Dantrolene—Necrosis—Doxorubicin—liver cancer	0.00243	0.00933	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.0024	0.00689	CbGpPWpGaD
Dantrolene—Dysgeusia—Sorafenib—liver cancer	0.00239	0.00916	CcSEcCtD
Dantrolene—Extravasation—Epirubicin—liver cancer	0.00237	0.00907	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.00235	0.00672	CbGpPWpGaD
Dantrolene—Dysphonia—Doxorubicin—liver cancer	0.00232	0.0089	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TP53—liver cancer	0.0023	0.00661	CbGpPWpGaD
Dantrolene—Anaemia—Sorafenib—liver cancer	0.00226	0.00865	CcSEcCtD
Dantrolene—RYR3—Ion channel transport—RAF1—liver cancer	0.00225	0.00646	CbGpPWpGaD
Dantrolene—Lacrimation increased—Epirubicin—liver cancer	0.00224	0.00858	CcSEcCtD
Dantrolene—Nocturia—Epirubicin—liver cancer	0.00223	0.00853	CcSEcCtD
Dantrolene—Extravasation—Doxorubicin—liver cancer	0.00219	0.00839	CcSEcCtD
Dantrolene—Leukopenia—Sorafenib—liver cancer	0.00219	0.00838	CcSEcCtD
Dantrolene—Atrioventricular block—Epirubicin—liver cancer	0.00213	0.00815	CcSEcCtD
Dantrolene—Hypertension—Sorafenib—liver cancer	0.00211	0.00808	CcSEcCtD
Dantrolene—Myalgia—Sorafenib—liver cancer	0.00208	0.00797	CcSEcCtD
Dantrolene—Lacrimation increased—Doxorubicin—liver cancer	0.00207	0.00794	CcSEcCtD
Dantrolene—Nocturia—Doxorubicin—liver cancer	0.00206	0.00789	CcSEcCtD
Dantrolene—Injection site reaction—Epirubicin—liver cancer	0.00205	0.00786	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—JUN—liver cancer	0.00204	0.00584	CbGpPWpGaD
Dantrolene—Dry mouth—Sorafenib—liver cancer	0.00203	0.00779	CcSEcCtD
Dantrolene—Anaphylactic shock—Sorafenib—liver cancer	0.00199	0.00764	CcSEcCtD
Dantrolene—Atrioventricular block—Doxorubicin—liver cancer	0.00197	0.00755	CcSEcCtD
Dantrolene—Thrombocytopenia—Sorafenib—liver cancer	0.00195	0.00748	CcSEcCtD
Dantrolene—Aplastic anaemia—Epirubicin—liver cancer	0.00194	0.00743	CcSEcCtD
Dantrolene—Anorexia—Sorafenib—liver cancer	0.0019	0.00728	CcSEcCtD
Dantrolene—Injection site reaction—Doxorubicin—liver cancer	0.0019	0.00728	CcSEcCtD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.00189	0.00542	CbGpPWpGaD
Dantrolene—Pulmonary oedema—Epirubicin—liver cancer	0.00184	0.00704	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00182	0.00696	CcSEcCtD
Dantrolene—Aplastic anaemia—Doxorubicin—liver cancer	0.00179	0.00687	CcSEcCtD
Dantrolene—Dyspepsia—Sorafenib—liver cancer	0.00175	0.00672	CcSEcCtD
Dantrolene—Phlebitis—Epirubicin—liver cancer	0.00174	0.00667	CcSEcCtD
Dantrolene—Decreased appetite—Sorafenib—liver cancer	0.00173	0.00664	CcSEcCtD
Dantrolene—Thrombophlebitis—Epirubicin—liver cancer	0.00173	0.00663	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00172	0.00493	CbGpPWpGaD
Dantrolene—Fatigue—Sorafenib—liver cancer	0.00172	0.00658	CcSEcCtD
Dantrolene—Pain—Sorafenib—liver cancer	0.0017	0.00653	CcSEcCtD
Dantrolene—Constipation—Sorafenib—liver cancer	0.0017	0.00653	CcSEcCtD
Dantrolene—Pulmonary oedema—Doxorubicin—liver cancer	0.0017	0.00651	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00167	0.00478	CbGpPWpGaD
Dantrolene—Hepatic failure—Epirubicin—liver cancer	0.00167	0.00639	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—CYCS—liver cancer	0.00166	0.00476	CbGpPWpGaD
Dantrolene—RYR1—Ion channel transport—RAF1—liver cancer	0.00166	0.00476	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00166	0.00476	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00164	0.0047	CbGpPWpGaD
Dantrolene—Gastrointestinal pain—Sorafenib—liver cancer	0.00163	0.00624	CcSEcCtD
Dantrolene—Phlebitis—Doxorubicin—liver cancer	0.00161	0.00617	CcSEcCtD
Dantrolene—Thrombophlebitis—Doxorubicin—liver cancer	0.0016	0.00614	CcSEcCtD
Dantrolene—Urticaria—Sorafenib—liver cancer	0.00158	0.00607	CcSEcCtD
Dantrolene—Abdominal pain—Sorafenib—liver cancer	0.00158	0.00604	CcSEcCtD
Dantrolene—Body temperature increased—Sorafenib—liver cancer	0.00158	0.00604	CcSEcCtD
Dantrolene—Hepatic failure—Doxorubicin—liver cancer	0.00154	0.00591	CcSEcCtD
Dantrolene—Cardiac failure—Epirubicin—liver cancer	0.00154	0.00588	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00153	0.0044	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—JUN—liver cancer	0.0015	0.0043	CbGpPWpGaD
Dantrolene—Diplopia—Epirubicin—liver cancer	0.0015	0.00574	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.0015	0.00574	CcSEcCtD
Dantrolene—Pain in extremity—Epirubicin—liver cancer	0.0015	0.00574	CcSEcCtD
Dantrolene—Hypersensitivity—Sorafenib—liver cancer	0.00147	0.00563	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00144	0.00414	CbGpPWpGaD
Dantrolene—Asthenia—Sorafenib—liver cancer	0.00143	0.00548	CcSEcCtD
Dantrolene—Cardiac failure—Doxorubicin—liver cancer	0.00142	0.00544	CcSEcCtD
Dantrolene—Pruritus—Sorafenib—liver cancer	0.00141	0.0054	CcSEcCtD
Dantrolene—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.00139	0.00398	CbGpPWpGaD
Dantrolene—Pain in extremity—Doxorubicin—liver cancer	0.00139	0.00531	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00139	0.00531	CcSEcCtD
Dantrolene—Diplopia—Doxorubicin—liver cancer	0.00139	0.00531	CcSEcCtD
Dantrolene—Diarrhoea—Sorafenib—liver cancer	0.00136	0.00522	CcSEcCtD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.00134	0.00383	CbGpPWpGaD
Dantrolene—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00133	0.00381	CbGpPWpGaD
Dantrolene—Muscular weakness—Epirubicin—liver cancer	0.00132	0.00506	CcSEcCtD
Dantrolene—Dizziness—Sorafenib—liver cancer	0.00132	0.00505	CcSEcCtD
Dantrolene—Dysphagia—Epirubicin—liver cancer	0.0013	0.00496	CcSEcCtD
Dantrolene—Eosinophilia—Epirubicin—liver cancer	0.00128	0.00491	CcSEcCtD
Dantrolene—Vomiting—Sorafenib—liver cancer	0.00127	0.00486	CcSEcCtD
Dantrolene—Rash—Sorafenib—liver cancer	0.00126	0.00481	CcSEcCtD
Dantrolene—Dermatitis—Sorafenib—liver cancer	0.00126	0.00481	CcSEcCtD
Dantrolene—Headache—Sorafenib—liver cancer	0.00125	0.00478	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—liver cancer	0.00123	0.00353	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—CYCS—liver cancer	0.00122	0.00351	CbGpPWpGaD
Dantrolene—Muscular weakness—Doxorubicin—liver cancer	0.00122	0.00469	CcSEcCtD
Dantrolene—Dysphagia—Doxorubicin—liver cancer	0.0012	0.00459	CcSEcCtD
Dantrolene—Pollakiuria—Epirubicin—liver cancer	0.0012	0.00458	CcSEcCtD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00119	0.00342	CbGpPWpGaD
Dantrolene—Eosinophilia—Doxorubicin—liver cancer	0.00119	0.00455	CcSEcCtD
Dantrolene—Nausea—Sorafenib—liver cancer	0.00118	0.00454	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—PPARA—liver cancer	0.00117	0.00334	CbGpPWpGaD
Dantrolene—Drowsiness—Epirubicin—liver cancer	0.00116	0.00442	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.00115	0.00328	CbGpPWpGaD
Dantrolene—Renal failure—Epirubicin—liver cancer	0.00114	0.00435	CcSEcCtD
Dantrolene—Sweating—Epirubicin—liver cancer	0.00111	0.00424	CcSEcCtD
Dantrolene—Pollakiuria—Doxorubicin—liver cancer	0.00111	0.00424	CcSEcCtD
Dantrolene—Haematuria—Epirubicin—liver cancer	0.0011	0.00422	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.00109	0.00311	CbGpPWpGaD
Dantrolene—Drowsiness—Doxorubicin—liver cancer	0.00107	0.00409	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—HMOX1—liver cancer	0.00106	0.00305	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00106	0.00304	CbGpPWpGaD
Dantrolene—Renal failure—Doxorubicin—liver cancer	0.00105	0.00402	CcSEcCtD
Dantrolene—Haemoglobin—Epirubicin—liver cancer	0.00104	0.00399	CcSEcCtD
Dantrolene—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.00104	0.00298	CbGpPWpGaD
Dantrolene—Hepatitis—Epirubicin—liver cancer	0.00104	0.00397	CcSEcCtD
Dantrolene—Haemorrhage—Epirubicin—liver cancer	0.00104	0.00397	CcSEcCtD
Dantrolene—Sweating—Doxorubicin—liver cancer	0.00102	0.00393	CcSEcCtD
Dantrolene—Haematuria—Doxorubicin—liver cancer	0.00102	0.0039	CcSEcCtD
Dantrolene—Visual impairment—Epirubicin—liver cancer	0.000999	0.00383	CcSEcCtD
Dantrolene—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.000998	0.00286	CbGpPWpGaD
Dantrolene—Haemoglobin—Doxorubicin—liver cancer	0.000964	0.00369	CcSEcCtD
Dantrolene—Flushing—Epirubicin—liver cancer	0.000962	0.00369	CcSEcCtD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.00096	0.00275	CbGpPWpGaD
Dantrolene—Hepatitis—Doxorubicin—liver cancer	0.000959	0.00368	CcSEcCtD
Dantrolene—Haemorrhage—Doxorubicin—liver cancer	0.000959	0.00368	CcSEcCtD
Dantrolene—Chills—Epirubicin—liver cancer	0.00093	0.00356	CcSEcCtD
Dantrolene—Visual impairment—Doxorubicin—liver cancer	0.000925	0.00354	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000909	0.00261	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—liver cancer	0.000907	0.0026	CbGpPWpGaD
Dantrolene—Erythema—Epirubicin—liver cancer	0.000903	0.00346	CcSEcCtD
Dantrolene—Flushing—Doxorubicin—liver cancer	0.00089	0.00341	CcSEcCtD
Dantrolene—Tension—Epirubicin—liver cancer	0.000886	0.00339	CcSEcCtD
Dantrolene—Dysgeusia—Epirubicin—liver cancer	0.000884	0.00339	CcSEcCtD
Dantrolene—Nervousness—Epirubicin—liver cancer	0.000877	0.00336	CcSEcCtD
Dantrolene—Back pain—Epirubicin—liver cancer	0.000873	0.00334	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ALB—liver cancer	0.000867	0.00249	CbGpPWpGaD
Dantrolene—Chills—Doxorubicin—liver cancer	0.000861	0.0033	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—PPARA—liver cancer	0.00086	0.00247	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000859	0.00246	CbGpPWpGaD
Dantrolene—Vision blurred—Epirubicin—liver cancer	0.000851	0.00326	CcSEcCtD
Dantrolene—Ill-defined disorder—Epirubicin—liver cancer	0.000837	0.00321	CcSEcCtD
Dantrolene—Erythema—Doxorubicin—liver cancer	0.000835	0.0032	CcSEcCtD
Dantrolene—Anaemia—Epirubicin—liver cancer	0.000834	0.0032	CcSEcCtD
Dantrolene—Tension—Doxorubicin—liver cancer	0.00082	0.00314	CcSEcCtD
Dantrolene—Dysgeusia—Doxorubicin—liver cancer	0.000818	0.00313	CcSEcCtD
Dantrolene—Malaise—Epirubicin—liver cancer	0.000814	0.00312	CcSEcCtD
Dantrolene—Nervousness—Doxorubicin—liver cancer	0.000811	0.00311	CcSEcCtD
Dantrolene—Leukopenia—Epirubicin—liver cancer	0.000808	0.0031	CcSEcCtD
Dantrolene—Back pain—Doxorubicin—liver cancer	0.000808	0.00309	CcSEcCtD
Dantrolene—Vision blurred—Doxorubicin—liver cancer	0.000787	0.00302	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—RAF1—liver cancer	0.000784	0.00225	CbGpPWpGaD
Dantrolene—Convulsion—Epirubicin—liver cancer	0.000782	0.003	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—UGDH—liver cancer	0.000781	0.00224	CbGpPWpGaD
Dantrolene—Hypertension—Epirubicin—liver cancer	0.000779	0.00299	CcSEcCtD
Dantrolene—Ill-defined disorder—Doxorubicin—liver cancer	0.000775	0.00297	CcSEcCtD
Dantrolene—Anaemia—Doxorubicin—liver cancer	0.000772	0.00296	CcSEcCtD
Dantrolene—Myalgia—Epirubicin—liver cancer	0.000768	0.00294	CcSEcCtD
Dantrolene—Discomfort—Epirubicin—liver cancer	0.000759	0.00291	CcSEcCtD
Dantrolene—Malaise—Doxorubicin—liver cancer	0.000753	0.00289	CcSEcCtD
Dantrolene—Dry mouth—Epirubicin—liver cancer	0.000752	0.00288	CcSEcCtD
Dantrolene—Leukopenia—Doxorubicin—liver cancer	0.000748	0.00286	CcSEcCtD
Dantrolene—Confusional state—Epirubicin—liver cancer	0.000743	0.00285	CcSEcCtD
Dantrolene—Anaphylactic shock—Epirubicin—liver cancer	0.000737	0.00282	CcSEcCtD
Dantrolene—Convulsion—Doxorubicin—liver cancer	0.000724	0.00277	CcSEcCtD
Dantrolene—Thrombocytopenia—Epirubicin—liver cancer	0.000721	0.00276	CcSEcCtD
Dantrolene—Hypertension—Doxorubicin—liver cancer	0.000721	0.00276	CcSEcCtD
Dantrolene—Tachycardia—Epirubicin—liver cancer	0.000719	0.00275	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000714	0.00205	CbGpPWpGaD
Dantrolene—Hyperhidrosis—Epirubicin—liver cancer	0.000712	0.00273	CcSEcCtD
Dantrolene—Myalgia—Doxorubicin—liver cancer	0.000711	0.00272	CcSEcCtD
Dantrolene—Discomfort—Doxorubicin—liver cancer	0.000703	0.00269	CcSEcCtD
Dantrolene—Anorexia—Epirubicin—liver cancer	0.000702	0.00269	CcSEcCtD
Dantrolene—Dry mouth—Doxorubicin—liver cancer	0.000695	0.00266	CcSEcCtD
Dantrolene—Confusional state—Doxorubicin—liver cancer	0.000687	0.00263	CcSEcCtD
Dantrolene—Anaphylactic shock—Doxorubicin—liver cancer	0.000682	0.00261	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000671	0.00257	CcSEcCtD
Dantrolene—Thrombocytopenia—Doxorubicin—liver cancer	0.000667	0.00256	CcSEcCtD
Dantrolene—Insomnia—Epirubicin—liver cancer	0.000666	0.00255	CcSEcCtD
Dantrolene—Tachycardia—Doxorubicin—liver cancer	0.000665	0.00255	CcSEcCtD
Dantrolene—Hyperhidrosis—Doxorubicin—liver cancer	0.000659	0.00252	CcSEcCtD
Dantrolene—Somnolence—Epirubicin—liver cancer	0.000655	0.00251	CcSEcCtD
Dantrolene—Anorexia—Doxorubicin—liver cancer	0.00065	0.00249	CcSEcCtD
Dantrolene—Dyspepsia—Epirubicin—liver cancer	0.000648	0.00248	CcSEcCtD
Dantrolene—Decreased appetite—Epirubicin—liver cancer	0.00064	0.00245	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ALB—liver cancer	0.000639	0.00183	CbGpPWpGaD
Dantrolene—Fatigue—Epirubicin—liver cancer	0.000635	0.00243	CcSEcCtD
Dantrolene—Pain—Epirubicin—liver cancer	0.00063	0.00241	CcSEcCtD
Dantrolene—Constipation—Epirubicin—liver cancer	0.00063	0.00241	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000621	0.00238	CcSEcCtD
Dantrolene—Insomnia—Doxorubicin—liver cancer	0.000616	0.00236	CcSEcCtD
Dantrolene—Feeling abnormal—Epirubicin—liver cancer	0.000607	0.00233	CcSEcCtD
Dantrolene—Somnolence—Doxorubicin—liver cancer	0.000606	0.00232	CcSEcCtD
Dantrolene—Gastrointestinal pain—Epirubicin—liver cancer	0.000602	0.00231	CcSEcCtD
Dantrolene—Dyspepsia—Doxorubicin—liver cancer	0.0006	0.0023	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000597	0.00171	CbGpPWpGaD
Dantrolene—Decreased appetite—Doxorubicin—liver cancer	0.000593	0.00227	CcSEcCtD
Dantrolene—Fatigue—Doxorubicin—liver cancer	0.000588	0.00225	CcSEcCtD
Dantrolene—Urticaria—Epirubicin—liver cancer	0.000585	0.00224	CcSEcCtD
Dantrolene—Constipation—Doxorubicin—liver cancer	0.000583	0.00223	CcSEcCtD
Dantrolene—Pain—Doxorubicin—liver cancer	0.000583	0.00223	CcSEcCtD
Dantrolene—Abdominal pain—Epirubicin—liver cancer	0.000582	0.00223	CcSEcCtD
Dantrolene—Body temperature increased—Epirubicin—liver cancer	0.000582	0.00223	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—RAF1—liver cancer	0.000578	0.00166	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000577	0.00165	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000569	0.00163	CbGpPWpGaD
Dantrolene—Feeling abnormal—Doxorubicin—liver cancer	0.000562	0.00215	CcSEcCtD
Dantrolene—Gastrointestinal pain—Doxorubicin—liver cancer	0.000557	0.00214	CcSEcCtD
Dantrolene—Hypersensitivity—Epirubicin—liver cancer	0.000543	0.00208	CcSEcCtD
Dantrolene—Urticaria—Doxorubicin—liver cancer	0.000541	0.00207	CcSEcCtD
Dantrolene—Abdominal pain—Doxorubicin—liver cancer	0.000539	0.00206	CcSEcCtD
Dantrolene—Body temperature increased—Doxorubicin—liver cancer	0.000539	0.00206	CcSEcCtD
Dantrolene—Asthenia—Epirubicin—liver cancer	0.000529	0.00202	CcSEcCtD
Dantrolene—Pruritus—Epirubicin—liver cancer	0.000521	0.002	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000513	0.00147	CbGpPWpGaD
Dantrolene—Diarrhoea—Epirubicin—liver cancer	0.000504	0.00193	CcSEcCtD
Dantrolene—Hypersensitivity—Doxorubicin—liver cancer	0.000502	0.00192	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000494	0.00141	CbGpPWpGaD
Dantrolene—Asthenia—Doxorubicin—liver cancer	0.000489	0.00187	CcSEcCtD
Dantrolene—Dizziness—Epirubicin—liver cancer	0.000487	0.00187	CcSEcCtD
Dantrolene—Pruritus—Doxorubicin—liver cancer	0.000482	0.00185	CcSEcCtD
Dantrolene—Vomiting—Epirubicin—liver cancer	0.000468	0.00179	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000468	0.00134	CbGpPWpGaD
Dantrolene—Diarrhoea—Doxorubicin—liver cancer	0.000466	0.00179	CcSEcCtD
Dantrolene—Rash—Epirubicin—liver cancer	0.000464	0.00178	CcSEcCtD
Dantrolene—Dermatitis—Epirubicin—liver cancer	0.000464	0.00178	CcSEcCtD
Dantrolene—Headache—Epirubicin—liver cancer	0.000461	0.00177	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000456	0.00131	CbGpPWpGaD
Dantrolene—Dizziness—Doxorubicin—liver cancer	0.000451	0.00173	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000448	0.00129	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000442	0.00127	CbGpPWpGaD
Dantrolene—Nausea—Epirubicin—liver cancer	0.000438	0.00168	CcSEcCtD
Dantrolene—Vomiting—Doxorubicin—liver cancer	0.000433	0.00166	CcSEcCtD
Dantrolene—Rash—Doxorubicin—liver cancer	0.00043	0.00165	CcSEcCtD
Dantrolene—Dermatitis—Doxorubicin—liver cancer	0.000429	0.00164	CcSEcCtD
Dantrolene—Headache—Doxorubicin—liver cancer	0.000427	0.00164	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000415	0.00119	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.00041	0.00118	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000409	0.00117	CbGpPWpGaD
Dantrolene—Nausea—Doxorubicin—liver cancer	0.000405	0.00155	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000404	0.00116	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.0004	0.00115	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000386	0.00111	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000381	0.00109	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000376	0.00108	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000336	0.000963	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.00032	0.000916	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000305	0.000874	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000248	0.000712	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000245	0.000702	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000228	0.000654	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000205	0.000587	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000202	0.000579	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000188	0.00054	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000186	0.000532	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000178	0.000512	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000176	0.000505	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UGDH—liver cancer	0.000134	0.000383	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—EPT1—liver cancer	0.000126	0.00036	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TAT—liver cancer	0.000119	0.000341	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GLUL—liver cancer	8.09e-05	0.000232	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CPT1B—liver cancer	8.09e-05	0.000232	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NR1H4—liver cancer	7.8e-05	0.000224	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA3—liver cancer	7.67e-05	0.00022	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA4—liver cancer	7.01e-05	0.000201	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA2—liver cancer	6.83e-05	0.000196	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA1—liver cancer	6.59e-05	0.000189	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAT2—liver cancer	6.52e-05	0.000187	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALDOB—liver cancer	6.25e-05	0.000179	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CRABP1—liver cancer	5.96e-05	0.000171	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPGDS—liver cancer	5.21e-05	0.000149	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PSMA4—liver cancer	4.65e-05	0.000133	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PSMD10—liver cancer	4.65e-05	0.000133	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GOT2—liver cancer	4.52e-05	0.00013	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2E1—liver cancer	4.25e-05	0.000122	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYCS—liver cancer	3.98e-05	0.000114	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GOT1—liver cancer	3.9e-05	0.000112	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GGT1—liver cancer	3.9e-05	0.000112	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTP1—liver cancer	3.5e-05	0.0001	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HMOX1—liver cancer	3.46e-05	9.91e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM1—liver cancer	3.22e-05	9.23e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1A1—liver cancer	3.05e-05	8.75e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTHFR—liver cancer	2.85e-05	8.16e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARA—liver cancer	2.79e-05	8e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CG—liver cancer	2.39e-05	6.85e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARG—liver cancer	2.31e-05	6.61e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CD—liver cancer	2.1e-05	6.02e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALB—liver cancer	2.07e-05	5.95e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CB—liver cancer	1.83e-05	5.25e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CA—liver cancer	1.12e-05	3.2e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKT1—liver cancer	9.12e-06	2.62e-05	CbGpPWpGaD
